Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael A Postow

Showing results (41-50 of 212) with videos related to

Pageof 22
Sort By:
JAMA Oncology|July 2, 2016
Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A ReviewClaire F Friedman, Tracy A Proverbs-Singh, Michael A Postow
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 20, 2024
Breaking the Mold: Trailblazing Melanoma Therapy Beyond Checkpoint Through Innovative ApproachesNeiha Kidwai, Monica Chen, Michael A Postow, et al.
Frontiers in Immunology|January 28, 2022
Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in MelanomaKimberly Loo, James W Smithy, Michael A Postow, et al.
Journal for Immunotherapy of Cancer|October 29, 2014
Ipilimumab in patients with melanoma and autoimmune diseaseChrisann Kyi, Richard D Carvajal, Jedd D Wolchok, et al.
Endocrine-Related Cancer|March 11, 2014
Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institutionMabel Ryder, Margaret Callahan, Michael A Postow, et al.
Current Oncology Reports|August 13, 2013
Checkpoint modulation in melanoma: an update on ipilimumab and future directionsDavid B Page, Michael A Postow, Margaret K Callahan, et al.
Oncology (Williston Park, N.Y.)|November 13, 2014
CTLA-4 antibodies: new directions, new combinationsSamuel A Funt, David B Page, Jedd D Wolchok, et al.
Melanoma Management|September 8, 2018
Targeting immune checkpoints in melanoma: an updateRodrigo R Munhoz, Alejandro Falcón González, Vanessa A Reed, et al.
Science Translational Medicine|March 27, 2015
On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activationAlexander M Lesokhin, Margaret K Callahan, Michael A Postow, et al.
The Oncologist|June 29, 2022
Melanoma-Specific Clinical Outcomes of Inpatient Immune Checkpoint Blockade TreatmentKimberly Loo, Hannah L Kalvin, Katherine S Panageas, et al.
Pageof 22

Showing results (41-50 of 212) with videos related to

Sort By:
Pageof 22
JAMA Oncology|July 2, 2016
Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A ReviewClaire F Friedman, Tracy A Proverbs-Singh, Michael A Postow
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 20, 2024
Breaking the Mold: Trailblazing Melanoma Therapy Beyond Checkpoint Through Innovative ApproachesNeiha Kidwai, Monica Chen, Michael A Postow, et al.
Frontiers in Immunology|January 28, 2022
Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in MelanomaKimberly Loo, James W Smithy, Michael A Postow, et al.
Journal for Immunotherapy of Cancer|October 29, 2014
Ipilimumab in patients with melanoma and autoimmune diseaseChrisann Kyi, Richard D Carvajal, Jedd D Wolchok, et al.
Endocrine-Related Cancer|March 11, 2014
Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institutionMabel Ryder, Margaret Callahan, Michael A Postow, et al.
Current Oncology Reports|August 13, 2013
Checkpoint modulation in melanoma: an update on ipilimumab and future directionsDavid B Page, Michael A Postow, Margaret K Callahan, et al.
Oncology (Williston Park, N.Y.)|November 13, 2014
CTLA-4 antibodies: new directions, new combinationsSamuel A Funt, David B Page, Jedd D Wolchok, et al.
Melanoma Management|September 8, 2018
Targeting immune checkpoints in melanoma: an updateRodrigo R Munhoz, Alejandro Falcón González, Vanessa A Reed, et al.
Science Translational Medicine|March 27, 2015
On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activationAlexander M Lesokhin, Margaret K Callahan, Michael A Postow, et al.
The Oncologist|June 29, 2022
Melanoma-Specific Clinical Outcomes of Inpatient Immune Checkpoint Blockade TreatmentKimberly Loo, Hannah L Kalvin, Katherine S Panageas, et al.
Pageof 22